Skip to content

Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients

A randomized, double-blind, placebo-controlled, multicentre clinical study on the improvement of novel coronavirus pneumonia (COVID-19) convalescent sleep mood disorder with shumian capsule

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003233
Enrollment
Unknown
Registered
2020-04-23
Start date
2020-05-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Hubei Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. COVID-19 convalescent diagnostic criteria; 2. Cured and discharged patients more than 2 weeks; 3. Aged from 18 to 70 years; 4. Those with insomnia, anxiety, depression and other sleep mood disorders as the main clinical manifestations, and those with two symptoms at the same time, or visual analogue scale (VAS) of single symptom >=4; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with difficulty in taking oral drugs due to basic diseases; 2. Accompanied by severe basic diseases affecting survival, including uncontrolled clinically significant heart, lung, kidney, digestion, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, and severe malnutrition; 3. Allergic constitution, allergic to the drugs involved in the treatment plan; 4. Pregnant or lactating women; 5. Mental state: unable to cooperate, suffering from mental illness, no self-knowledge, and unable to express clearly; 6. Participants in other clinical trials; 7. According to the judgment of the researcher, there will be patients with complicated enrollment or poor compliance, which will affect the efficacy and safety evaluation.

Design outcomes

Primary

MeasureTime frame
Visual analog score of symptoms;

Countries

China

Contacts

Public ContactBa Yuanming

Hubei Provincial Hospital of TCM

1723426138@qq.com+86 13871013338

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026